| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.36▼ | 2.39▼ | 2.40▼ | 3.37▼ | 3.54▼ |
| MA10 | 2.39▼ | 2.42▼ | 2.46▼ | 3.78▼ | 3.80▼ |
| MA20 | 2.42▼ | 2.49▼ | 2.57▼ | 4.04▼ | 2.86▼ |
| MA50 | 2.51▼ | 3.27▼ | 3.70▼ | 4.12▼ | 1.55▲ |
| MA100 | 2.57▼ | 3.73▼ | 4.03▼ | 2.75▼ | 2.22▲ |
| MA200 | 3.30▼ | 4.07▼ | 4.03▼ | 1.68▲ | 8.10▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.008▼ | 0.039▲ | 0.025▲ | -0.228▼ | -0.146▼ |
| RSI | 27.524▼ | 20.124▼ | 20.199▼ | 28.709▼ | 47.538▼ |
| STOCH | 9.578▼ | 3.333▼ | 5.831▼ | 41.047 | 28.021 |
| WILL %R | -82.353▼ | -89.655▼ | -92.500▼ | -99.003▼ | -73.340 |
| CCI | -185.855▼ | -170.866▼ | -159.527▼ | -177.141▼ | -117.025▼ |
|
Thursday, February 19, 2026 07:46 AM
Moleculin Biotech Inc (NASDAQ:MBRX) saw its stock tumble 34.3% in premarket trading Thursday after announcing agreements with certain warrant holders to immediately exercise existing warrants. Under ...
|
|
Thursday, February 19, 2026 06:56 AM
Moleculin is currently advancing a Phase 3 clinical trial called MIRACLE, evaluating its lead program Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid ...
|
|
Thursday, February 19, 2026 06:02 AM
HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/02/26 | 2.42 | 2.49 | 2.29 | 2.32 | 225,323 |
| 20/02/26 | 2.61 | 2.62 | 2.41 | 2.46 | 546,105 |
| 19/02/26 | 3.15 | 3.16 | 2.55 | 2.68 | 2,166,187 |
| 18/02/26 | 4.78 | 5.30 | 4.65 | 4.81 | 514,701 |
| 17/02/26 | 4.40 | 4.70 | 4.33 | 4.56 | 69,344 |
| 13/02/26 | 4.24 | 4.40 | 4.1001 | 4.34 | 68,973 |
| 12/02/26 | 4.16 | 4.2601 | 4.07 | 4.216 | 25,175 |
| 11/02/26 | 4.12 | 4.20 | 4.03 | 4.18 | 36,925 |
| 10/02/26 | 4.17 | 4.34 | 4.12 | 4.14 | 25,623 |
| 09/02/26 | 4.36 | 4.3699 | 4.10 | 4.12 | 43,277 |
|
|
||||
|
|
||||
|
|